Revolution Medicines Inc. (NASDAQ: RVMD) announced it will present preclinical data on a new class of mutant-targeted catalytic RAS inhibitors ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE